Y-mAbs Therapeutics Stock Price, Forecast & Analysis (NASDAQ:YMAB)

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

4 equities research analysts have issued 12-month price targets for Y-mAbs Therapeutics' shares. Their forecasts range from $38.00 to $40.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $39.33 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Press coverage about YMAB stock has trended somewhat positive on Tuesday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,080,000 shares, an increase of 29.4% from the September 30th total of 834,400 shares. Based on an average daily trading volume, of 200,200 shares, the days-to-cover ratio is currently 5.4 days. Currently, 7.6% of the shares of the stock are short sold. View Y-mAbs Therapeutics' Current Options Chain.

Some companies that are related to Y-mAbs Therapeutics include Arrowhead Pharmaceuticals (ARWR), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Allakos (ALLK), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Alkermes (ALKS), FibroGen (FGEN), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT) and Evotec (EVTCY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Evoke Pharma (EVOK), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), CTI BioPharma (CTIC) and Fate Therapeutics (FATE).

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Alps Advisors Inc. (0.20%), Strs Ohio (0.06%), Rhumbline Advisers (0.06%), Tuttle Tactical Management (0.03%) and California Public Employees Retirement System (0.03%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

YMAB stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, Tuttle Tactical Management, California Public Employees Retirement System and Rhumbline Advisers. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $28.64.

Y-mAbs Therapeutics has a market capitalization of $1.14 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]